American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

Novartis has cash for a big pharma deal—but here’s why it’s not buying

by admin February 1, 2025
February 1, 2025
Novartis has cash for a big pharma deal—but here’s why it’s not buying

Novartis AG (SWX: NOVN) has the cash to opt for a large deal in pursuit of accelerated growth – but it’s just not interested in one, according to its chief executive Vasant Narasimhan.

That’s because the bigger deals have historically not paid off in the pharmaceutical sector.

“They significantly disrupt R&D; synergies don’t materialize,” he said in a CNBC interview today.

But that doesn’t mean the Swiss giant will avoid smaller, bolt-on acquisitions.

CEO Narasimhan’s remarks arrive shortly after the pharma company reported better-than-expected sales for its fiscal fourth quarter.

Its shares gained as much as 3% on Friday.

Novartis on the lookout for new bolt-on acquisitions

Novartis has made more than 30 tuck-in acquisitions over the past two years – but it remains open to more in 2025.  

That’s because bolt-on acquisitions bring new technologies and more talent into the company. “The only way we’ll discover the next breakthrough is having great people,” the chief executive added.

He touted the uptick in the company’s free cash flow, valuation, and growth rates following the recent spin-offs, adding “We have proved the strategy is working.”

Instead of spending more on acquisitions, Novartis will use the free cash flow to grow its dividend and buyback stock to create more value for its shareholders, according to CEO Narasimhan.

Novartis stock currently pays a dividend yield of 3.40%.

Novartis is interested in next-gen therapies

In terms of bolt-on acquisitions, Novartis will particularly go “aggressively” after a deal that adds next-generation therapies (radioligen, cell/gene, RNA) to its portfolio.

Other areas of interest for the company include cardiovascular diseases, oncology, immunology, and neuroscience.

Novartis currently attributes about 40% to external sales – but “I’m comfortable if that goes to 50%,” according to CEO Vasant Narasimhan.  

He attributed lackluster stock performance in recent years to an “overshift into AI.” But the company is moving in the right direction and the strength of its fundamentals will eventually start to reflect in the share price, the chief executive added.

Artificial intelligence and Novartis

Vasant Narasimhan agreed that artificial intelligence will likely have a significant influence on the healthcare industry, particularly in terms of accelerating drug discovery.

However, it’s important to keep AI in perspective, he argued.

In general, we’re at 10 out of 1,000 projects that we take and research ultimately gets through to registration. If we could get that to 20, that would be amazing. But it’s still 20 out of 1,000.

For the current year, Novartis forecasts mid to high single-digit growth in its net sales and high single to low double-digit growth in its core operating income.

Note that Novartis stock is currently up only 6.0% versus its price in early 2020. Late last year, Novartis said it was not interested in joining the weight-loss drugs race.

The post Novartis has cash for a big pharma deal—but here’s why it’s not buying appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
LinkedIn AI data lawsuit dropped after company denies misuse
next post
How will OPEC respond to Trump’s oil request?

Related Posts

China’s Neta and Zeekr inflated EV sales using...

July 20, 2025

Dow tumbles 475 points, S&P 500 suffers worst...

April 18, 2024

XRP breakout timeline narrows as bulls eye $3.00...

June 25, 2025

Clothing chain Bob’s Stores closing after 70 years

July 5, 2024

5 of the best Stanley Druckenmiller stocks in...

September 11, 2024

Meta to pay $25 million to Trump to...

January 30, 2025

Reece James’ net worth in 2025: how much...

March 25, 2025

Europe markets open: Stoxx 600 down; EasyJet loss...

May 22, 2025

Elon Musk confirms Tesla Robotaxi pilot launching in...

June 21, 2025

XRP price prediction: analyst eyes another 600% rally,...

June 19, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • How Donald Trump’s immigration crackdown may tank the labor market

      August 4, 2025
    • Trump’s tariff threat looms over India’s Russian oil deals

      August 4, 2025
    • Trump moves nuclear submarines near Russia: what triggered the move and what’s ahead

      August 3, 2025
    • BOE rate cuts offer little relief as UK households face mounting financial strain

      August 3, 2025
    • Retail investors shift focus to Europe as US valuations stretch

      August 3, 2025

    Categories

    • Business (3,583)
    • Investing (2,703)
    • Latest News (2,031)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved